Literature DB >> 32295143

Copper-Promoted One-Pot Approach: Synthesis of Benzimidazoles.

S N Murthy Boddapati1,2, Ramana Tamminana3, Ravi Kumar Gollapudi1, Sharmila Nurbasha1, Mohamed E Assal4, Osamah Alduhaish4, Mohammed Rafiq H Siddiqui4, Hari Babu Bollikolla1, Syed Farooq Adil4.   

Abstract

A facile, one-pot, and proficient method was developed for the production of various 2-arylaminobenzimidazoles. This methodology is based for the first time on a copper catalyst promoted domino C-N cross-coupling reaction for the generation of 2-arylaminobenzimidazoles. Mechanistic investigations revealed that the synthetic pathway involves a copper-based desulphurization/nucleophilic substitution and a subsequent domino intra and intermolecular C-N cross-coupling reactions. Some of the issues typically encountered during the synthesis of 2-arylaminobezimidazoles, including the use of expensive catalytic systems and the low reactivity of bromo precursors, were addressed using this newly developed copper-catalyzed method. The reaction procedure is simple, generally with excellent substrate tolerance, and provides good to high yields of the desired products.

Entities:  

Keywords:  2-aminoaryl benzimidazole; copper catalyst; desulfurization; domino C–Ncross-coupling; homogeneous catalysis

Mesh:

Substances:

Year:  2020        PMID: 32295143      PMCID: PMC7221555          DOI: 10.3390/molecules25081788

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Heterocyclic compounds like benzimidazoles are very important molecules that can be found in a number of natural and synthetically prepared biologically active compounds such as 3-chloro-1-5-(2-methyl-1H-bezimidazol-2-yl)-4-(substituted) phenylazetidin-2-one (an antimicrobial compound [1]), 5, 6-dichloro-1-(β-d-ribofuranosyl)benzimidazoles(an antiviral agent [2]), pyrimidyl-thio-methyl-benzimidazole(an antiulcer molecule [3]), 1-ethyl-2-(4-phenyl)phenyl-1H-benzo[d]imidazole(an antiasthmatic compound [4]), and 1-butyl-2-(3,4-dihydro-4,4-dimethyl-2H-thiochromyl)phenyl-1H-benzo[d]imidazole (an anti-diabetic molecule [4]), shown in Figure 1. Furthermore, these compounds have been identified in N-methyl-d-aspartate (NMDA) antagonists [5], in analgesic [6], anti-inflammatory [7], anti-cancer [8] drugs, in factor Xa(FXa) inhibitors [9], in poly(ADP-ribose)polymerase (PARP) inhibitors [10] and in non-peptide thrombin inhibitordrugs [11].
Figure 1

Examples of some biologically active benzimidazoles.

Thus, enormous efforts have been focused on the preparation of benzimidazole structural frameworks. Classical methods may involve (i) the inter cyclocondensation of 2-aminophenylaniline precursors with either carboxylic acids or aldehydes followed by oxidation [12], (ii) the diazotization on 1-benzimidazolylidenehydrazine [13], (iii) the cyclocondensation of esters with diaminobenzene under microwave irradiation [14], (iv) the reductive cyclization of o-nitroaniline with aldehyde using sodium dithionite [15] and (v) a solid-phase route [16]. However, most of these protocols suffer from major shortcomings such as limited suitable substituents for diverse synthesis, strong alkaline conditions, troublesome management of the chemical process, and elevated temperature. Therefore, we reasoned that a catalytic approach involving CN bond formation would overcome the abovementioned disadvantages. In the past decade, efficient methods have been described for the synthesis of heterocyclic compounds by aryl halides with copper catalysts [17,18]. Buchwald and co-authors developed the preparation of indulines [19], 2-aryl-4-quinolones [20] and N-alkylbenzimidazoles [21]. The group of Ma described a cascade approach for the production of benzofurans [22], dihydrobenzimidazole-2-ones [23], benzimidazoles [24], isoquinolines [25], pyrrolo [1,2-a]quinoxaline [26], and indoles [27]. Intramolecular C–X bond formation has been established by Batey’s group to synthesize benzoxazoles [28], benzothiazoles [29] and aminobenzimidazoles [30]. In addition, CN bond formation has been well explored using various transition metals such as copper [31,32], palladium [33], cobalt [34], zinc [35], ruthenium [36] for the production of various heterocycles, but, to the best of our knowledge, no report is available on the synthesis of substituted 2-aminophenylbenzimidazoles employing a copper catalyst through the reporting strategy. Very recently, 2-phenylaminobenzimidazoles have been reported from thiourea using cobalt catalysis [37]; however, they have failed to develop from bromo precursors. Therefore, in continuation of our research towards the development of efficient methodologies for the synthesis of heterocycles [38,39], herein, we developed a methodology for the synthesis of 2-phenylamino benzimidazoles from molecules having a bromo moiety, under moderate reaction conditions using copper catalysis. Another advantage of our method is the use of copper, which is cheaper, more air-stable and more easily available than cobalt.

2. Results and Discussion

In this context, 2-phenylaminobenzimidazoles were prepared from thiourea through an approach consisting of consecutive desulphurization/nucleophilic substitution and CN cross-coupling. Thiourea reacted with 2-bromoaniline at room temperature using copper salt as a catalyst to give N-(2-bromophenyl)-guanidine, which further underwent a domino intra and intermolecular CN cross-coupling reaction with aryliodide to yield the desired product 2-phenylaminobenzimidazole 1a (Scheme 1). Optimization was achieved by taking thiourea and bromoaniline as model substrates and using various solvents, bases, ligands, and copper salts at different temperatures. We were pleased to observe that thiourea gave 2-bromoguanidine in quantitative conversion using NaOAc as a base and both copper (I) and copper (II) salts in the presence of DMSO/DMF at room temperature. The reaction was further continued at room temperature using K2CO3 (2 equiv) as a base, Cu salt (20 mol%), ligand L4 (20 mol%) for 18 h. Unfortunately, no target product was observed (Table 1, entry 1). Later, the reaction was performed at 50 °C, however, no product formed (Table 1, entry 2). In contrast, target product 1a was observed in 15% yield when the reaction was carried out at 80 °C (Table 1, entry 3). The yield of the product increased to 52% when the reaction was conducted at 100 °C (Table 1, entry 4). Very interestingly, the reaction provided the desired product 1a quantitatively at 120 °C (Table 1, entry 5).
Scheme 1

Synthetic route for the synthesis of N-phenyl-1H-benzo[d]imidazol-2-amine.

Table 1

Optimization of the reaction for the synthesis of 2-aminophenyl benzoimidazole a.

EntryCopper SaltBaseTemp °CLigandConversion e 1aYield (%) g
1CuIK2CO3RTL4n.d. f-
2CuIK2CO350L4n.d. f-
3CuIK2CO380L42015
4CuIK2CO3100L45552
5CuIK2CO3120L410096
6CuIKOH120L47166
7CuICs2CO3 b120L410096
8CuBrK2CO3120L410094
9CuClK2CO3120L410096
10CuSO4·5H2OK2CO3120L410095
11Cu(OAc)2·H2OK2CO3120L410096
12CuSO4·5H2OK2CO3120-106
13CuSO4·5H2OK2CO3120L13024
14CuSO4·5H2OK2CO3120L25056
15CuSO4·5H2OK2CO3120L31511
16CuSO4·5H2O K2CO3120L55548
17CuSO4·5H2O cK2CO3120L44036
18CuSO4·5H2OK2CO3 d120L45552
19-K2CO3120L4n.d. f-

a Reaction conditions: Step-1: Thiourea (1 mmol); DMSO/DMF (2 mL); NaOAc (1 equiv); copper salt (50 mol%), 1 h, room temperature; 2-bromo aniline (2 mmol), room temperature, 4 h; Step-2: iodo benzene (1 mmol); copper salt (20 mol%); ligand (20 mol%); base (2 mmol) 18 h,temp; b Cs2CO3 (2.0 equiv); c copper salt (10 mol.%); d K2CO3 (1.0 equiv); e conversion based on diagnostic peaks integration in 1HNMR of crude reaction mixture; f n.d. = not detected; gisolated yield.

Bases like K2CO3 and Cs2CO3 were found to be effective for the reaction (Table 1, entries 5 and 7), whereas KOH was less effective (Table 1, entry 6). All the tested copper salts, i.e., CuI, CuBr, CuCl, CuSO4·5H2O, Cu(OAc)H2O, exhibited similar catalytic activity (Table 1, entries 5 and 8–11). Among the tested ligands, L4 was efficient (Table 1, entry 5), while the other ligands L1–L3 and L5 provided the target product in lower yields (Table 1, entries 13–16). In contrast, the reaction didnot proceed in the absence of ligand (Table 1, entry 12). By lowering the quantity of the copper source (10 mol%) or of the base (1.0 equiv), the reaction led to N-arylation, affording a lower amount of the target product (Table 1, entries 17–18). Control experiments also confirmed that the reaction could not yield the target product in the absence of a catalyst, and the intermediate 2-bromophenylguanidine was recovered intact (Table 1, entry 19). This control experiments demonstrated that the reaction requires a catalyst. Despite the similar catalytic activity of all the copper salts tested, considering the cost effectiveness of CuSO4·5H2O over the other examined catalysts, the authors chosen CuSO4·5H2O as a reasonable copper source for both step 1 and step 2 in Scheme 1. Finally, the total outcome of the above optimization studies is presented in Scheme 2.
Scheme 2

Optimized synthetic pathway for the synthesis of 2-phenylaminobenzimidazole from thiourea.

The compound 1a was further confirmed based on spectral data, for example, the appearance of characteristic peaks at 1542(m), 1478(s), 1413(s) cm−1, clearlyshowing Ar–C=C stretching, a peak at 3098(w) cm−1 showing aromatic =CH stretching, and peak at 3294(s) cm−1 indicating –N–H stretching. In the 1H NMR spectrum of compound 1a, adoublet at δ 7.78 ppm and amultiplet at δ 7.26–7.11 ppm were assigned to aromatic protons, and a broad singlet at δ 6.12 ppm (br s, 1H) to a –N–H proton. This spectral data allowed determining the structure of compound 1a as N-Phenyl-1H-benzo[d]imidazol-2-amine, which was further confirmed by its 13C NMR spectrum which exposed 11 signals between δ 139.2 and 110.8 ppm, indicates the existence of 11 different carbons in the compound. Further, the formation of compound 1a was supported by the molecular ion peak at 210.10[M + H]+ in its mass spectrum (EI). Next, to validate the efficiency of the protocol, we investigated the substrate scope towards the production of 15 more 2-arylaminobenzimidazoles 1b–1p under optimized conditions, and the results are indicated in Figure 2. N-(2-bromophenyl)-guanidine was reacted with various derivatives of aryl iodide having 2-CH3, 3-CH3, 4-CH3, 4-OCH3, 4-COOCH3, 4-Cl, 2,4-DiCH3, 2,6-DiCH3 and naphthyl to obtain the final products 1b–1j in 62–97% yields. Similarly, the reaction of 2-bromoaniline holding substituents such as 2-Me, 3-Me, 4-Me, 4-CN readily provided the desired products 1k–1n in 56–96% yields. In addition, several substrates were tested to understand the reactivity of aryl halides. For example, thiourea reacted with 4-chloro-2-bromoaniline to provide guanidine which consecutively underwent a CN cross-coupling reaction with 4-methyliodobenzene and 4-nitroiodobenzene to afford the target products 1o and 1p in 79% and 62% yields respectively. The above mentioned results clearly confirmed that the substrates having electron-donating and electron-withdrawing groups are compatible with this process, affording the substituted 2-aminobenzimidazoles in moderate to excellent yield. All the spectroscopic and analytical data of the synthesized compounds were in full agreement with the anticipated structures.
Figure 2

Substrate scope evaluation; Reaction conditions: thiourea (1 mmol); DMSO (2 mL); NaOAc (1 equiv); CuSO4·5H2O (50 mol%), 1 h, room temperature; 2-bromo aniline/substituted 2-bromo aniline (2 mmol), room temperature, 4 h; Next, ArI (1 mmol); CuSO4·5H2O (20 mol%); 1,10-Phenanthroline (20 mol%); K2CO3 (2 mmol); 18 h; 120 °C; a Isolated yield.

The reaction of aryl halides was next examined under optimized reaction conditions. Iodobenzene afforded the target product 1a in 96% yield (Equation (1)). On the other hand, bromobenzene led to the target product 1a in 12% yield and to the product 2-aminobenzimidazole B in 81% yield (Equation (2)). However, no target product could be obtained when using chlorobenzene, which provided 2-aminobenzimidazole B in 97% yield (Equation (3)). In addition, we also examined the activity of different haloanilines. It was observed that 2-iodoaniline readily reacted with thiourea to give iodoguanidine C, which required a shorter reaction time than bromoguanidine to undergo a domino CN cross-coupling reaction with iodobenzene, affording the desired product 1a in 96% yield (Equation (4)). However, 2-chloroaniline gave the intermediate chloroguanidine D in complete conversion, but no domin O CN cross-coupled product was observed with iodobenzene under optimized reaction conditions (Equation (5)). To reveal the mechanism, control experiments were conducted. The reaction was performed in the absence of aryl iodide and resulted inthe intramolecular CN cyclized product 2-aminobenzimidazole B in 97% yield (Equation (6)) under optimized reaction conditions. Furthermore, 2-aminobenzimidazole readily reacted with iodobenzene under optimized conditions to afford the target product 1a in 96% yield (Equation (7)). The above results clearly suggested that thiourea treated with 2-bromoaniline to provide N-(2-bromophenyl)-guanidine A gave first the intramolecular CN cyclised product 2-amino benzimidazole B, which reacted with iodobenzene to providethe final product 1a by an intermolecular CN cross-coupling reaction. Moreover, the formation of the key intermediate B was confirmed based on its spectral data. In fact, in the IR spectrum of compound B, thepeaks at 3421(w) and 3396(w) cm−1 corresponds to N–H stretching, the peak at 3063(w) cm−1 represents –C=C–H stretching, the peaks at 1626(s), 1530(s), 1444(s) cm−1 correspond to Ar–C=C stretching; 1H-NMR analysis showed a broad signal at δ 5.62(2H) ppm, indicating amino protons and signals between δ7.58 and 7.09 ppm representing aromatic protons. Moreover, in the 13C NMR spectrum, seven signals between δ167.0 and 118.2 ppm also confirmed that compound B is 1H-benzo[d]imidazol-2-amine. Finally, the structure of B was confirmed by the appearanceof a peak at m/z 134.07 [M + H]+ in its mass spectrum (EI). Based on these experimental investigations and the available literature [37,40,41,42,43,44,45,46,47,48,49,50], the mechanism for the formation of the final product 2-phenylaminobenzimidazole is very much similar to the mechanism reported for cobalt catalysis [37] (see supporting information Scheme S1).

3. Experimental

3.1. Material and Methods

General information: 2-bromoaniline, iodobenzene, CuSO4∙5H2O (98%), CuI (98%), CuBr (98%), Cu2O (97%), CuCl (99%), Cu(OAc)2∙H2O (98%), sodium acetate, KOH, K2CO3, and Cs2CO3 were purchased from Sigma-Aldrich (St. Luis, MO, USA) and were used without further purification. The solvents were purchased and dried according to standard procedures prior to use. The reactions were monitored by using pre-coated Merck60 F254 (Merck, Darmstadt, Germany) TLC silica gel plates with 0.25 mm thickness. Column chromatography was performed for purification, utilizing silica gel (60–120 mesh, Merck, Darmsadt, Germany). A Cintex melting point apparatus (Cintex, Mumbai, India) was used to determine the melting points. Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum one FT-IR spectrometer (Perkin Elmer, Waltham, Massachusetts, USA). A Varian 400 MHz spectrometer (Varian, Palo Alto, CA, USA) was utilized to record the 1H NMR and 13C-NMR spectra in CDCl3/DMSO-d6. Chemical shifts are presented in δ ppm, employing TMS as internal reference. A Jeol SX-102 spectrometer (JEOL Ltd., Akishima, Tokyo, Japan) was used to record the Mass spectra.

3.2. General Procedure for the Synthesis of 2-(N-arylamino)Benzimidazole

To a stirred solution of DMSO (2–3 mL), thiourea (1 mmol, 76 mg) was added slowly, followed by the addition of NaOAc (1 mmol, 82 mg) and a copper source (50 mol%) at room temperature. The whole reaction mixture was stirred for 1 h (until a black-colored solution was obtained) at room temperature. To this, 2-bromoaniline (2 mmol, 344 mg) was added. After completion of the reaction (monitored by TLC), the reaction mixture was transferred into tubes and the mixture was centrifuged for 10 min. A black solid was then recovered from the tubes, and to this a clear solution of iodobenzene (1 mmol, 204 mg), K2CO3 (2 mmol, 277 mg), Cu(SO)4.5H2O (20 mol%, 50 mg), and 1,10-phenanthroline (20 mol%, 36 mg) was added slowly in several minutes, and the reaction mixture was then allowed to stir for 18 h at 120 °C. Progress of the reaction was monitored by TLC, using ethyl acetate and hexane (1:4). After completion of the reaction, the reaction mixture was cooled to room temperature. Then, the solution was washed with ethyl acetate (7 mL) and water (3 mL) for 5 times. The organic layer was evaporated, and the crude reaction mixture was purified on asilica gel (60–120 mesh) column by chromatography to obtain the final product 2-(N-arylamino)benzimidazole, which was characterized by NMR (1H and 13C), IR, and mass spectral data. N-Phenyl-1H-benzo[d]imidazol-2-amine (1a): White solid; yield 96%; mp 97–99 °C; 1H NMR (400 MHz, CDCl3) δ 7.78 (d,J = 6.8 Hz, 2H), 7.26–7.11 (m, 7H), 6.12 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 139.2, 137.2, 134.2, 132.6, 130.5, 129.9, 129.7, 127.3, 115.0, 114.7, 110.8; FT-IR (KBr) 3294, 3098, 1676, 1618, 1597, 1542, 1478, 1413, 1253, 1076 cm−1. m/z (ESI–MS) 210.10 [M + H]+. N-O-Tolyl-1H-benzo[d]imidazol-2-amine (1b): White solid; yield 87%; mp 151–152 °C; 1H NMR (400 MHz, DMSO) δ 7.35 (d, J = 12 Hz, 1H), 7.25–7.19 (m, 2H), 7.00 (d,J = 7.4 Hz, 2H), 6.88–6.77 (m, 3H), 2.18 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.2, 137.5, 137.1, 135.7, 133.9, 132.2, 131.6, 130.9, 129.0, 125.3, 123.2, 118.2, 115.2, 20.7; FT-IR (KBr) 3314, 2924, 2859, 3109, 2115, 1619, 1509, 1330, 1250, 1112, 1088, 1025 cm−1. m/z (ESI–MS) 224.11 [M + H]+. N-m-Tolyl-1H-benzo[d]imidazol-2-amine (1c): White solid; yield 91%; mp 148–149 °C; 1H NMR (400 MHz, CDCl3) δ 7.55 (s, 1H), 7.43–7.34 (m, 3H), 7.31–7.25 (m, 3H), 6.70 (br s, 1H), 2.36 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 149.0, 139.4, 137.4, 134.9, 134.7, 133.6, 133.1, 130.5, 124.0, 122.0, 115.5, 113.1, 110.4, 20.6; FT-IR (KBr) 3257, 3191, 2958, 1501, 1495, 1403, 1386, 1341, 1286, 1061 cm−1. m/z (ESI–MS) 224.11 [M + H]+. N-p-Tolyl-1H-benzo[d]imidazol-2-amine (1d): White solid; yield 95%; mp 145–147 °C; 1H NMR (400 MHz, CDCl3) δ 7.45–7.32 (m, 6H), 7.12 (d,J = 8 Hz, 2H), 5.98 (br s, 1H), 2.29 (s, 3H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 152.3, 142.2, 135.9, 133.0, 130.8, 129.8, 128.7, 128.5, 123.2, 120.6, 117.8, 20.0; FT-IR (KBr) 3256, 3121, 2963, 1643, 1586, 1514, 1367, 1234, 1136, 1094, 1017 cm−1. m/z (ESI–MS) 224.11 [M + H]+. N-(4-Methoxyphenyl)-1H-benzo[d]imidazol-2-amine (1e): White solid; yield 97%; mp 153–154 °C; 1H NMR (400 MHz, CDCl3) δ 7.47–7.42 (m, 3H), 7.30–7.16 (m, 2H), 7.14–7.08 (m, 3H), 7.00 (br s, 1H), 3.87 (s, 3H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 154.7, 153.1, 142.9, 133.7, 132.6, 129.7, 129.5, 129.3, 126.1, 121.3, 114.9, 55.02; FT-IR (KBr) 3345, 2958, 2857, 1567, 1535, 1506, 1321, 1271, 1235, 1182, 1123, 1074, 1033 cm−1. m/z (ESI–MS) 240.11 [M + H]+. Methyl 4-(1H-benzo[d]imidazol-2-ylamino)benzoate (1f): White solid; yield 62%; mp 207–209 °C; 1H NMR (300 MHz, d6-DMSO, ppm) δ 7.64–7.51 (m, 3H), 6.83–6.61 (m, 5H), 5.83 (br s, 1H), 3.83 (s, 3H);13C NMR (75 MHz, d6-DMSO) d = 166.3, 152.7, 145.7, 144.2, 141.3, 132.3, 131.2, 128.1, 119.8, 119.1, 106.6, 106.3, 45.3; FT-IR (KBr) 3234, 3157, 2853, 1658, 1599, 1516, 1428, 1411, 1242, 1197, 1121, 1087, 1065, 1022 cm−1. m/z (ESI-MS) 268.10 [M + H]+. N-(4-Chlorophenyl)-1H-benzo[d]imidazol-2-amine (1g): White solid; yield 77%; mp 158–159 °C; 1H NMR (400 MHz, CDCl3) δ 7.77–7.50 (m, 4H), 7.26 (d, J = 7.6 Hz, 2H), 7.16 (d, J= 8.8 Hz, 2H), 4.66 (br s, 1H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 151.1, 141.7, 136.9, 132.3, 128.3, 128.1, 127.7, 127.0, 124.7, 120.0, 118.1; FT-IR (KBr) 3076, 2958, 2150, 1637, 1504, 1421, 1374, 1330, 1256, 1207, 1030 cm−1. m/z (ESI–MS) 245.05 [M + H]+. N-(2,4-Dimethylphenyl)-1H-benzo[d]imidazol-2-amine (1h): White solid; yield 90%; mp 143–144 °C;1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.38–7.33 (m, 3H), 7.27–7.09 (m, 3H), 6.74 (br s, 1H), 2.28 (s, 3H), 2.27 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 141.3, 138.3, 137.2, 136.9, 132.9, 132.4, 130.6, 127.2, 117.7, 115.1, 111.2, 21.4, 20.4; FT-IR (KBr) 3278, 3201, 2922, 2858, 1607, 1581, 1453, 1410, 1389, 1268, 1155, 1018 cm−1. m/z (ESI–MS) 238.13 [M + H]+. N-(2,6-Dimethylphenyl)-1H-benzo[d]imidazol-2-amine (1i): White solid; yield 82%; mp 148–149 °C; 1H NMR (400 MHz, CDCl3) δ 7.22–7.17 (m, 2H), 7.13 (d,J = 8.4 Hz, 2H), 7.06–6.97 (m, 3H), 6.35 (br s, 1H), 2.43 (s, 6H), 2.18 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 142.8, 135.2, 134.4, 134.3, 130.5, 130.1, 129.5, 128.7, 118.4, 115.5, 111.2, 24.5, 20.7; FT-IR (KBr) 3094, 2921, 2867, 2222, 1574, 1486, 1456, 1374, 1241, 1208, 1027 cm−1. m/z (ESI–MS) 238.13 [M + H]+. N-(Naphthalen-3-yl)-1H-benzo[d]imidazol-2-amine (1j): White solid; yield 78%; mp 168–169 °C; 1H NMR (400 MHz, CDCl3) δ 8.02–7.63 (m, 5H), 7.51–7.47 (m, 3H), 7.35 (d, J = 8 Hz, 1H), 7.26 (d, J = 5.2 Hz, 2H), 6.60 (br s, 1H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 154.6, 142.6, 134.2, 133.8, 133.6, 131.2, 129.4, 129.1, 128.8, 128.3, 127.8, 127.2, 125.8, 125.4, 122.4, 121.1, 120.8. m/z (ESI–MS) 260.11 [M + H]+. 4-Methyl-N-phenyl-1H-benzo[d]imidazol-2-amine (1k): White solid; yield 90%; mp 151–153 °C;1H NMR (400 MHz, CDCl3) δ 7.47-7.25 (m, 4H), 7.07 (d, J = 7.6 Hz, 2H), 6.94 (d, J = 8 Hz, 1H), 6.74 (br s, 1H), 6.54 (s, 1H), 2.35 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 146.7, 139.5, 135.5, 134.4, 132.8, 129.7, 128.7, 126.4, 124.5, 117.9, 110.0, 21.8; FT-IR (KBr) 3290, 3144, 2984, 2917, 2859, 1604, 1584, 1498, 1449, 1413, 1391, 1289, 1270, 1213, 1153, 1057, 934 cm−1. m/z (ESI–MS) 224.11 [M + H]+. 5-Methyl-N-phenyl-1H-benzo[d]imidazol-2-amine (1l): White solid; yield 93%; mp 151–153 °C; 1H NMR (400 MHz, CDCl3) δ 7.76–7.49 (m, 4H), 7.25–6.85 (m, 4H), 2.37 (s, 3H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 151.6, 141.5, 135.7, 134.8, 132.2, 128.3, 128.0, 127.8, 119.9, 118.0, 114.3, 19.1; FT-IR (KBr) 3306, 2920, 2847, 1603, 1515, 1444, 1302, 1236, 1302, 1236, 1191, 1115, 1095, 1020 cm−1. m/z (ESI–MS) 224.11 [M + H]+. 6-Methyl-N-phenyl-1H-benzo[d]imidazol-2-amine (1m): White solid; yield 96%; mp 146–147 °C; 1H NMR (400 MHz, CDCl3) δ 7.40 (s, 1H), 7.30–7.19 (m, 5H), 7.04–7.01 (m, 2H), 6.81 (br s, 1H), 2.32 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.0, 137.4, 135.3, 134.1, 132.7, 129.6, 127.0, 126.7, 115.3, 110.0, 20.3; FT-IR (KBr) 3285, 3056, 2854, 1603, 1574, 1534, 1497, 1456, 1321, 1234, 1121, 1085 cm−1. m/z (ESI–MS) 224.11 [M + H]+. 2-(Phenylamino)-3H-benzo[d]imidazole-5-carbonitrile (1n): White solid: yield 56%; mp 169–170 °C; 1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.29–7.22 (m, 3H), 7.16 (d, J = 6.8 Hz, 2H), 6.97 (d, J = 7.2 Hz, 2H), 6.84 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 139.2, 137.3, 134.2, 132.6, 130.5, 130.0, 129.7, 127.3, 115.0, 114.8, 111.0, 110.9; FT-IR (KBr) 3253, 3198, 1654, 1588, 1488, 1407, 1317, 1287, 1164, 1019, 927 cm−1. m/z (ESI–MS) 235.09 [M + H]+. 6-Chloro-N-p-tolyl-1H-benzo[d]imidazol-2-amine (1o): White solid: yield 79%; mp 151–152 °C; 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.50 (t, J = 9.2 Hz, 2H), 7.26 (d, J = 7.6 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H), 4.66 (br s, 1H), 2.40 (s, 3H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 151.1, 141.7, 136.9, 132.3, 128.3, 128.1, 127.7, 127.0, 124.7, 120.0, 118.1, 19.2; FT-IR (KBr) 3076, 2958, 2150, 1637, 1504, 1421, 1374, 1330, 1256, 1207, 1030 cm−1. m/z (ESI–MS) 259.12 [M + H]+. 6-Chloro-N-(4-nitrophenyl)-1H-benzo[d]imidazol-2-amine(1p): White solid: yield 62%; mp 178–180 °C; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 2.0 Hz, 1H), 7.47–7.37 (m, 3H), 7.10 (d, J = 9.2 Hz, 1H), 6.94 (br s, 1H), 6.81 (dd, J = 7.2, 2.4 Hz, 2H); 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ 153.9, 152.1, 135.8, 131.9, 131.2, 130.1, 129.9, 127.9, 121.8, 119.2, 112.7; FT-IR (KBr) 3275, 3085, 2834, 1607, 1579, 1486, 1302, 1233, 1179, 1085, 1036 cm−1. m/z (ESI–MS) 290.04 [M + H]+. 1H-benzo[d]imidazol-2-amine(B): White solid; mp 129–130 °C; 1H NMR (400 MHz, CDCl3) δ 7.58–7.56 (td, J = 8.0, 0.4 Hz, 1H), 7.53–7.50 (dd, J = 8.0, 0.8 Hz, 1H), 7.31–7.27 (m, 1H), 7.13–7.09 (d, J = 7.6, 1.2 Hz, 1H), 5.62 (br s, 2H); 13C NMR (100 MHz, CDCl3) δ 167.0, 151.9, 131.0, 125.5, 121.4, 120.6, 118.2; FT-IR (KBr) 3421, 3396, 3063, 1626, 1530, 1444, 1309, 1105 cm−1. m/z (ESI–MS) 134.07 [M + H]+.

4. Conclusions

In conclusion, we have developed a methodology for the synthesis of substituted 2-aminophenyl benzimidazoles from thiourea through a multistep reaction. This methodology involves consecutive a desulphurization/nucleophilic substitution and domino intra and inter molecular CN cross-coupling reaction. Control experiments were performed to understand themechanism. Many researchers have reported reactions for the generationof benzimidazoles; however, the simplicity, environmental acceptability, and cost effectiveness of copper makes this method more practical. Although the single yields look moderate, considering that the reaction consists of multiple processes, the yields are in fact good to high.
  37 in total

1.  Synthesis of indolines via a domino Cu-catalyzed amidation/cyclization reaction.

Authors:  Ana Minatti; Stephen L Buchwald
Journal:  Org Lett       Date:  2008-06-04       Impact factor: 6.005

2.  Microwave-assisted synthesis of benzimidazoles, benzoxazoles, and benzothiazoles from resin-bound esters.

Authors:  Hee-Jong Lim; Do Myung; Ihl Young Choi Lee; Myung Hee Jung
Journal:  J Comb Chem       Date:  2008-06-12

3.  Cobalt-catalyzed cross-coupling reactions.

Authors:  Gérard Cahiez; Alban Moyeux
Journal:  Chem Rev       Date:  2010-03-10       Impact factor: 60.622

4.  Domino condensation/S-arylation/heterocyclization reactions: copper-catalyzed three-component synthesis of 2-N-substituted benzothiazoles.

Authors:  Dawei Ma; Xu Lu; Liu Shi; Hui Zhang; Yongwen Jiang; Xiangqian Liu
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-22       Impact factor: 15.336

5.  Generation of iminyl copper species from alpha-azido carbonyl compounds and their catalytic C-C bond cleavage under an oxygen atmosphere.

Authors:  Shunsuke Chiba; Line Zhang; Gim Yean Ang; Benjamin Wei-Qiang Hui
Journal:  Org Lett       Date:  2010-05-07       Impact factor: 6.005

6.  Cobalt-catalyzed intramolecular C-N and C-O cross-coupling reactions: synthesis of benzimidazoles and benzoxazoles.

Authors:  Prasenjit Saha; Md Ashif Ali; Pokhraj Ghosh; Tharmalingam Punniyamurthy
Journal:  Org Biomol Chem       Date:  2010-10-20       Impact factor: 3.876

7.  Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.

Authors:  A W White; R Almassy; A H Calvert; N J Curtin; R J Griffin; Z Hostomsky; K Maegley; D R Newell; S Srinivasan; B T Golding
Journal:  J Med Chem       Date:  2000-11-02       Impact factor: 7.446

8.  Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6 type.

Authors:  R B Baudy; H Fletcher; J P Yardley; M M Zaleska; D R Bramlett; R P Tasse; D M Kowal; A H Katz; J A Moyer; M Abou-Gharbia
Journal:  J Med Chem       Date:  2001-05-10       Impact factor: 7.446

9.  Crystal structures and vibrational spectroscopy of copper(I) thiourea complexes.

Authors:  Graham A Bowmaker; John V Hanna; Chaveng Pakawatchai; Brian W Skelton; Yupa Thanyasirikul; Allan H White
Journal:  Inorg Chem       Date:  2009-01-05       Impact factor: 5.165

10.  Cascade coupling/cyclization process to N-substituted 1,3-dihydrobenzimidazol-2-ones.

Authors:  Benli Zou; Qiliang Yuan; Dawei Ma
Journal:  Org Lett       Date:  2007-09-15       Impact factor: 6.005

View more
  2 in total

1.  A directing group switch in copper-catalyzed electrophilic C-H amination/migratory annulation cascade: divergent access to benzimidazolone/benzimidazole.

Authors:  Hasina Mamataj Begam; Shantanu Nandi; Ranjan Jana
Journal:  Chem Sci       Date:  2022-04-14       Impact factor: 9.969

Review 2.  Progress and prospects in copper-catalyzed C-H functionalization.

Authors:  Thaipparambil Aneeja; Mohan Neetha; C M A Afsina; Gopinathan Anilkumar
Journal:  RSC Adv       Date:  2020-09-17       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.